Vimarsana
Biggest News Aggregation in the World

Rhui Zhou News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rhui Zhou. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rhui Zhou Today - Breaking & Trending Today

Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer - Vimarsana News

Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

Published: June 13, 2024

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

Source: lelezard.com
Related Topics:
Rhui ZhouAdimab IncyteEli LillyInnovent BiologicsNational Medical Products AdministrationPrnewswire Innovent Biologics IncMd Anderson Cancer CenterDrug AdministrationReceives Fast Track DesignationAdvanced PancreaticFast Track DesignationSenior Vice PresidentTrack Designation
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting - Vimarsana News

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

Published: June 2, 2024

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company…

Source: sina.com.hk
Related Topics:
Rhui ZhouUnited StatesHong KongSanofi IncyteEli LillyWei LiInnovent BiologicsCaicun ZhouChina National Medical Products AdministrationMd Anderson Cancer CenterDrug AdministrationNational Medical Products AdministrationInnovent Or CompanyDepartment Of Oncology At Shanghai East HospitalTongji UniversityInnovent Biologics IncAmerican Society Of Clinical OncologyClinical OncologyDrug EvaluationPrincipal InvestigatorShanghai East HospitalSenior Vice PresidentBreakthrough Therapy DesignationsPriority Review DesignationsNew Drug Applications
Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual ... - Vimarsana News

Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual ...

Published: June 2, 2024

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceut

Source: menafn.com
Related Topics:
Rhui ZhouHong KongUnited StatesEli LillyInnovent BiologicsCaicun ZhouSanofi IncyteWei LiDrug AdministrationNational Medical Products AdministrationDepartment Of Oncology At Shanghai East HospitalInnovent Or CompanyTongji UniversityChina National Medical Products AdministrationMd Anderson Cancer CenterAmerican Society Of Clinical OncologyPrnewswire Innovent Biologics IncInnovent Biologics IncClinical OncologyDrug EvaluationPrincipal InvestigatorShanghai East HospitalSenior Vice PresidentBreakthrough Therapy DesignationsPriority Review Designations
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting - Vimarsana News

Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting

Published: June 2, 2024

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Source: prnewswire.com
Related Topics:
Yu ChenRhui ZhouUnited StatesInnovent BiologicsTingbo LiangSanofi IncyteEli LillyPrnewswire Innovent Biologics IncZhejiang UniversitySchool Of MedicineEuropean Society For Medical OncologyMd Anderson Cancer CenterEuropean SocietyMedical OncologyVirtual PlenarySenior Vice PresidentColorectal CancerFujian Cancer HospitalFirst Affiliated Hospital
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer - Vimarsana News

Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer

Published: June 2, 2024

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Source: prnewswire.com
Related Topics:
Rhui ZhouUnited StatesInnovent BiologicsHana ClaudinEli LillyXianjun YuSanofi IncyteInnovent Or CompanyNational Medical Products AdministrationAmerican Society Of Clinical OncologyGastrointestinal Cancers CongressInnovent Biologics IncFudan University Shanghai Cancer CenterPrnewswire Innovent Biologics IncBiliary Cancer Working GroupMd Anderson Cancer CenterClinical OncologyAnnual MeetingCancers CongressSenior Vice PresidentBiliary Cancer Working